drugset / Trial / NCT01661556

Clinical Trial of Hydroquinone Versus Miconazol in Melasma

NCT01661556

RandomizedParallel-groupDouble-blindTreatment

Summary

Melasma is an acquired discoloration of the skin characterized by brown colour changes commonly on the face.The duration of this double-blind clinical trial will be 12 weeks. The control group will receive treatment with topical Hydroquinone (4%), and the other group topical miconazole. Miconazol has antimelanotic properties and can be used as treatment for melasma patients. The estimated number of subjects to be recruited and randomized for the study is at least 30. The purpose of this study is determine if there is a difference in the effectiveness of these two agents. Melasma Area and Severity Index (MASI) score will be assessed at the beginning of the study and at weeks 4, 8, and 12. Photographs, colorimetry and histological assessment will be also evaluated. Occurrence of adverse effects will also be recorded.

Timeline

Start
2011-10
Primary completion
2015-02
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydroquinone Small molecule 4 % Topical
Subject Miconazole Small molecule 2 % Topical